20/20 Biolabs is trading 12.44% up at $0.46; the report does not link the move to the company’s announcement.

  • On September 29, 2026, the company announced an investor webinar scheduled for October 7.
  • The webinar will cover the FDA advisory panel’s favorable vote on GRAIL’s Galleri test, the OneTest franchise model, and firefighter screening initiatives.
  • Major indices were mixed, so broader-market direction does not clearly explain the gain.